References
- Ripabelli G, Sammarco ML, D’Amico A, De Dona R, Iafigliola M, Parente A, Samprati N, Santagata A, Adesso C, Natale A, et al. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: results from an active pharmacovigilance study in central Italy. Hum Vaccin Immunother. 2022 Oct 31;2126668. Online ahead of print. doi:10.1080/21645515.2022.2126668.
- Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211047229. doi:10.1177/10760296211047229.
- Hilmy AI, Dey RK, Imad HA, Yoosuf AA, Nazeem A, Latheef AA. Coronavirus disease 2019 and dengue: two case reports. J Med Case Rep. 2021 Mar 26;15(1):171. doi:10.1186/s13256-021-02707-7.
- Joob B, Wiwanitkit V. Letter to the editor: Coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020 Mar;53(2):70. doi:10.3961/jpmph.20.065.
- Čiučiulkaitė I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, Siffert W, Lindemann M. GNB3 c.825c>t polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022 Aug 29;13:932043. doi:10.3389/fgene.2022.932043.